| Phase 2 trial of ibudilast in progressive multiple sclerosis RJ Fox, CS Coffey, R Conwit, ME Cudkowicz, T Gleason, A Goodman, ... New England Journal of Medicine 379 (9), 846-855, 2018 | 265 | 2018 |
| Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis RJ Fox, CS Coffey, ME Cudkowicz, T Gleason, A Goodman, EC Klawiter, ... Contemporary clinical trials 50, 166-177, 2016 | 74 | 2016 |
| Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab … M Rensel, A Zabeti, MA Mealy, D Cimbora, D She, J Drappa, E Katz Multiple Sclerosis Journal 28 (6), 925-932, 2022 | 51 | 2022 |
| Identification of proteins in human substantia nigra E Kitsou, S Pan, JP Zhang, M Shi, A Zabeti, DW Dickson, R Albin, ... PROTEOMICS–Clinical Applications 2 (5), 776-782, 2008 | 39 | 2008 |
| The functional polymorphism of the hemoglobin‐binding protein haptoglobin influences susceptibility to idiopathic Parkinson's disease P Costa‐Mallen, H Checkoway, A Zabeti, MJ Edenfield, PD Swanson, ... American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 147 …, 2008 | 35 | 2008 |
| Autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis F Nabizadeh, K Pirahesh, N Rafiei, F Afrashteh, MA Ahmadabad, A Zabeti, ... Neurology and Therapy 11 (4), 1553-1569, 2022 | 18 | 2022 |
| Association of disease-modifying therapies with COVID-19 susceptibility and severity in patients with multiple sclerosis: a systematic review and network meta-analysis M Barzegar, S Houshi, E Sadeghi, MS Hashemi, G Pishgahi, S Bagherieh, ... Multiple sclerosis international 2022, 2022 | 10 | 2022 |
| Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): A systematic review and meta-analysis S Bagherieh, A Afshari-Safavi, S Vaheb, M Kiani, EM Ghaffary, ... Neurological Sciences 44 (6), 1905-1915, 2023 | 8 | 2023 |
| Evaluation of shorter infusion times for ocrelizumab treatment in an extension substudy of the phase IIIb CHORDS trial R Bermel, E Waubant, G Pardo, A Bass, P Repovic, S Newsome, ... MULTIPLE SCLEROSIS JOURNAL 25, 779-780, 2019 | 8 | 2019 |
| Progressive myelopathy in myelin oligodendrocyte glycoprotein antibody-associated disease: A new mimicker of progressive multiple sclerosis? SB Marcucci, M Elkasaby, R Walch, A Zare-Shahabadi, A Mahammedi, ... Multiple Sclerosis and Related Disorders 52, 102964, 2021 | 7 | 2021 |
| Inebilizumab for treatment of neuromyelitis optica spectrum disorder M J Tullman, A Zabeti, S Vuocolo, Q Dinh Neurodegenerative Disease Management 11 (05), 341-352, 2021 | 6 | 2021 |
| Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial RA Bermel, E Waubant, G Pardo, A Bass, P Repovic, S Newsome, ... Annals of Clinical and Translational Neurology 8 (3), 711-715, 2021 | 4 | 2021 |
| A case of fatal invasive aspergillosis in a patient with neurosarcoidosis treated with infliximab C Van Sanford, AZ Obeidat, M Hagen, A Zabeti International Journal of Neuroscience 129 (6), 619-622, 2019 | 4 | 2019 |
| SPRINT-MS/NN 102 phase II trial of ibudilast in progressive MS: top-line results RJ Fox, CS Coffey, ME Cudkowicz, T Gleason, A Goodman, EC Klawiter, ... MULTIPLE SCLEROSIS JOURNAL 23, 979-980, 2017 | 4 | 2017 |
| Factors associated with COVID-19 susceptibility and severity in patients with multiple sclerosis: A systematic review M Barzegar, S bagherieh, S Houshi, MS Hashemi, G Pishgahi, ... medRxiv, 2021.06. 11.21258765, 2021 | 3 | 2021 |
| Sprint-MS/NN 102 Phase II Trial of Ibudilast in Progressive MS: Top-Line Results RT Naismith, CS Coffey, ME Cudkowicz, T Gleason, AD Goodman, ... ACTRIMS Forum 2018, 2018 | 2 | 2018 |
| An assessment on the use of infra-scanner for the diagnosis of the brain hematoma in head trauma S Esmaeili, M Mojtahed, Z Mirzaasgari, G Masoumi, SNR Alavi, ... The American Journal of Emergency Medicine 55, 174-179, 2022 | 1 | 2022 |
| Oral Microbiome and Multiple Sclerosis? A Novel Concept! S Esmaeili, S Esmaeili, A Zabeti European Journal of Dental and Oral Health 4 (6), 19-20, 2023 | | 2023 |
| Safety and efficacy of mesenchymal stem cell therapy in patients with multiple sclerosis during short-and long-term follow-up: a systematic review and meta-analysis S Vaheb, S Afshin, H Ghoshouni, ghaffary, elham moases, M Farzan, ... MULTIPLE SCLEROSIS JOURNAL 29, 1022-1022, 2023 | | 2023 |
| Molecular Biomarkers and cognitive impairment in multiple sclerosis: A Review S Esmaeili, AZ Obeidat, A Zabeti Biomarkers in Neuropsychiatry, 100077, 2023 | | 2023 |
